Skip to main content
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRS ISIN · US00461U1051 LEI · 5493000B2LQ9QTW1DF52 US Manufacturing
Filings indexed 844 across all filing types
Latest filing 2025-05-05 Director's Dealing
Country US United States of America
Listing US ACRS

About Aclaris Therapeutics, Inc.

https://www.aclaristx.com/

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel drug candidates for immuno-inflammatory diseases. The company leverages its core expertise in drug discovery, development, and kinase inhibition to create a pipeline of both small and large molecule drugs. Aclaris focuses on translating scientific discovery into innovative therapies to address the needs of patients with underserved conditions.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-05-05 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-05 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-04-30 English
ARS
Annual Report
2025-04-24 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes voting items for the upcoming Annual Meeting, such as election of directors, approval of executive compensation, amendments to the certificate of incorporation, equity incentive plan approval, and ratification of the independent auditor. The document is titled 'Definitive Additional Materials' related to the proxy statement and is not the proxy statement itself but additional materials for voting. The content focuses on soliciting shareholder votes and providing information for the meeting, which fits the definition of Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters, but it contains detailed voting proposals and instructions, not just an announcement of a report. Therefore, the correct classification is PSI with high confidence.
2025-04-24 English
DEF 14A
Proxy Solicitation & Information Statement
2025-04-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.